IT1244496B - Impiego terapeutico dei peptidi della somatostatina. - Google Patents

Impiego terapeutico dei peptidi della somatostatina.

Info

Publication number
IT1244496B
IT1244496B ITRM910115A ITRM910115A IT1244496B IT 1244496 B IT1244496 B IT 1244496B IT RM910115 A ITRM910115 A IT RM910115A IT RM910115 A ITRM910115 A IT RM910115A IT 1244496 B IT1244496 B IT 1244496B
Authority
IT
Italy
Prior art keywords
therapeutic use
somatostatin peptides
somatostatin
peptides
group
Prior art date
Application number
ITRM910115A
Other languages
English (en)
Inventor
Eric Paul Krenning
Steven Willem Jan Lamberts
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of ITRM910115A0 publication Critical patent/ITRM910115A0/it
Publication of ITRM910115A1 publication Critical patent/ITRM910115A1/it
Application granted granted Critical
Publication of IT1244496B publication Critical patent/IT1244496B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/16—Somatostatin; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Optics & Photonics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invenzione riguarda un nuovo impiego farmaceutico di peptidi di somatostatina comprendenti sul gruppo terminale ammino un gruppo poliamminopolicarbossilico, sotto forma libera o sotto forma di sale farmaceuticamente accettabile, in particolare nella preparazione d'un medicamento per il trattamento di disturbi con un'eziologia comprendente o associata con un eccesso della secrezione dell'ormone di crescita.
ITRM910115A 1990-02-22 1991-02-19 Impiego terapeutico dei peptidi della somatostatina. IT1244496B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909004017A GB9004017D0 (en) 1990-02-22 1990-02-22 Improvements in or relating to organic compounds

Publications (3)

Publication Number Publication Date
ITRM910115A0 ITRM910115A0 (it) 1991-02-19
ITRM910115A1 ITRM910115A1 (it) 1992-08-19
IT1244496B true IT1244496B (it) 1994-07-15

Family

ID=10671445

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM910115A IT1244496B (it) 1990-02-22 1991-02-19 Impiego terapeutico dei peptidi della somatostatina.

Country Status (9)

Country Link
US (1) US6123916A (it)
JP (1) JP3288055B2 (it)
BE (1) BE1004645A3 (it)
CH (1) CH683318A5 (it)
DE (1) DE4104308A1 (it)
FR (1) FR2658421B1 (it)
GB (2) GB9004017D0 (it)
HK (1) HK43497A (it)
IT (1) IT1244496B (it)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE181240T1 (de) * 1991-02-08 1999-07-15 Biomeasure Inc Verwendung von somatostatinanalogen zur behandlung von melanomen
US5650134A (en) * 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
US5583104A (en) * 1993-12-06 1996-12-10 Mayo Foundation For Medical Research And Education Treatment of proliferation of bile duct epithelium
US5686418A (en) * 1996-04-08 1997-11-11 Biomeasure Incorporated Prolonging survival of transplanted pancreatic cells
US6316414B1 (en) 2000-07-31 2001-11-13 Dabur Research Foundation Somatostatin analogs for the treatment of cancer
US20020156010A1 (en) * 2000-11-20 2002-10-24 Lustig Robert H. Method of treating obesity in adult patients exhibiting primary insulin hypersecretion
US10266579B2 (en) 2014-09-14 2019-04-23 Tel Hashomer Medical Research Infrastructure And Services Ltd. Synthetic somatostatin receptor ligands
EP3405429B1 (en) * 2016-01-21 2021-07-28 Ramot at Tel-Aviv University Ltd. Formation of functionalized nanoparticles by supramolecular co-assembly
EP3568205B1 (en) 2017-01-12 2023-08-16 Radiomedix Inc. Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes
US10596278B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
CN114401749B (zh) * 2020-06-29 2024-04-16 北京拓界生物医药科技有限公司 一种放射性核素标记物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30548A (en) * 1860-10-30 Tool-holdeb
US4812554A (en) * 1977-11-08 1989-03-14 Genentech, Inc. Somatostatin peptide conjugate
HUT42101A (en) * 1985-01-07 1987-06-29 Sandoz Ag Process for preparing stomatostatine derivatives and pharmaceutical compositions containing such compounds
US4725577A (en) * 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
US4853371A (en) * 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
CH679045A5 (it) * 1987-06-29 1991-12-13 Sandoz Ag
GB8719042D0 (en) * 1987-08-12 1987-09-16 Parker D Conjugate compounds
MY106120A (en) * 1988-12-05 1995-03-31 Novartis Ag Peptide derivatives.
US5382654A (en) * 1992-02-05 1995-01-17 Mallinckrodt Medical, Inc. Radiolabelled peptide compounds
EP0600992B1 (en) * 1991-08-29 2000-09-20 Mallinckrodt Medical, Inc. Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins
US5225180A (en) * 1991-09-10 1993-07-06 Diatech, Inc. Technetium-99m labeled somatostatin-derived peptides for imaging

Also Published As

Publication number Publication date
FR2658421A1 (fr) 1991-08-23
CH683318A5 (de) 1994-02-28
ITRM910115A0 (it) 1991-02-19
BE1004645A3 (fr) 1993-01-05
GB2241167B (en) 1994-06-15
ITRM910115A1 (it) 1992-08-19
FR2658421B1 (fr) 1995-01-20
GB2241167A (en) 1991-08-28
HK43497A (en) 1997-04-18
JPH05124979A (ja) 1993-05-21
DE4104308A1 (de) 1991-08-29
US6123916A (en) 2000-09-26
GB9004017D0 (en) 1990-04-18
JP3288055B2 (ja) 2002-06-04
GB9103344D0 (en) 1991-04-03

Similar Documents

Publication Publication Date Title
DE69831971D1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
ATE293453T1 (de) Verbindungen zur behandlung von sexuellen funktionsstörungen
IT1244496B (it) Impiego terapeutico dei peptidi della somatostatina.
BR9510168A (pt) Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição
IL99699A0 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
RU94016393A (ru) Пептиды, обладающие способностью к стимулированию высвобождения гормона роста, способ получения, фармацевтическая композиция, способ лечения
HUP0100815A2 (hu) Neurológiai és neuropszichiátriai rendellenességek kezelésére szolgáló gyógyszerkészítmények
LTIP1654A (en) Protein, biologically active hormone, pharmaceutical preparation
IT1252868B (it) Composizione farmaceutica anticefalalgica per somministrazione endonasale, procedimento per prepararla e suo impiego terapeutico
DE69433371D1 (de) Polypeptid, fähig zur Inhibierung der Bindung zwischen menschliches IL-6 und dessen Rezeptor
ES2061591T3 (es) Administracion intranasal de polipeptidos en forma pulverizada.
SE9503924D0 (sv) Novel opioid peptides
BR1100309A (pt) Peptìdeo e composição farmacêutica para promover a liberação de nìveis de hormÈnio de crescimento em animais
GB9806632D0 (en) Peptide factor
EP0377272A3 (en) Use of nalmefene or naltrexone in the manufacture of a medicament for the treatment of inflammation in an arthritic disease or associated inflammatory diseases
LV11985A (lv) Noteiktu cistina atvasinajumu farmakologiska izmantosana
NZ516477A (en) Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
NO912558L (no) Mucoadhesiv baerer for avlevering av terapeutiske midler.
NZ332829A (en) Use of a polypeptide corresponding to a serine threonine kinase receptor, ALK-7 for neurological diseases
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
IT1293583B1 (it) Uso dell'acido gammaidrossibutirrico per il trattamento delle sindromi demenziali
MX9303074A (es) Uso de la (e)-2-(p-fluorofenetil)-3-fluoroalilamina en el tratamiento de la enfermedad de elzheimer.
IT1223132B (it) Composizione farmaceutica per somministrazione nasale

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970226